1. Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys.
- Author
-
Eigege A, Noland GS, Adelamo SE, Nwodu K, Sallau A, Umaru J, Mancha BS, Davies E, Danboyi J, Kadimbo JA, Saka YA, Anagbogu I, Miri ES, and Richards FO
- Subjects
- Albendazole administration & dosage, Anthelmintics administration & dosage, Anthelmintics therapeutic use, Child, Child, Preschool, Female, Filaricides therapeutic use, Humans, Ivermectin administration & dosage, Male, Nigeria epidemiology, Retrospective Studies, Albendazole therapeutic use, Elephantiasis, Filarial epidemiology, Elephantiasis, Filarial prevention & control, Ivermectin therapeutic use, Mass Drug Administration, Population Surveillance
- Abstract
Following the halt of mass drug administration (MDA) for lymphatic filariasis (LF), the WHO recommends at least 4 years of post-treatment surveillance (PTS) to confirm that transmission recrudescence or importation does not occur. The primary means of evaluation during PTS is repeated transmission assessment surveys (TASs) conducted at 2- to 3-year intervals after TAS-1 stop-MDA surveys. This study reports the results of TAS-2 and TAS-3 surveys in Plateau and Nasarawa states (pop. 6.9 million) of Nigeria divided into a minimum of seven evaluation units (EUs) per TAS. A total of 26,536 first- and second-year primary school children (approximately 6-7 years old) were tested for circulating filarial antigen (CFA) between 2014 and 2017. Of 12,313 children tested in TAS-2 surveys, only five (0.04%) were CFA positive, with no more than two positive samples from any one EU, which was below the critical value of 20 per EU. Of 14,240 children tested in TAS-3 surveys, none (0%) were CFA positive. These results indicate that LF transmission remains below sustainable transmission levels and suggest that elimination of transmission has been achieved in Plateau and Nasarawa, Nigeria.
- Published
- 2020
- Full Text
- View/download PDF